CHEMBIO DIAGNOSTIC SYSTEMS, INC., A BIOSYNEX SUBSIDIARY, RECEIVES $1.8 MILLION CARB-X GRANT TO DEVELOP A RAPID DIAGNOSTIC TEST FOR TYPHOID FEVER Medford, N.Y., USA / Strasbourg, France – February 6,…
CHEMBIO DIAGNOSTIC SYSTESMS INC., A SUBSIDIARY OF BIOSYNEX, ANNOUNCES DUAL FDA SUBMISSION OF DPP® SYPHILIS TnT ASSAY FOLLOWING BREAKTHROUGH DEVICE DESIGNATION Medford, N.Y., USA / Strasbourg, France – January 22,…
CHEMBIO DIAGNOSTIC SYSTESMS INC., A SUBSIDIARY OF BIOSYNEX, RECEIVES A GRANT FOR DEVELOPMENT OF A RAPID POINT OF CARE TEST FOR PREECLAMPSIA Chembio Diagnostic System, Inc. (Chembio), a wholly owned…
FOOD AND DRUG ADMINISTRATION AWARDS BREAKTHROUGH DEVICE STATUS TO THE DPP® SYPHILIS TnT ASSAY Medford, N.Y. USA / Strasbourg, France – July 29, 2025 – Chembio Diagnostic Systems, Inc., a…
